WO2018026943A1 - Tlr9 targeted therapeutics - Google Patents
Tlr9 targeted therapeutics Download PDFInfo
- Publication number
- WO2018026943A1 WO2018026943A1 PCT/US2017/045140 US2017045140W WO2018026943A1 WO 2018026943 A1 WO2018026943 A1 WO 2018026943A1 US 2017045140 W US2017045140 W US 2017045140W WO 2018026943 A1 WO2018026943 A1 WO 2018026943A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tlr9
- cancer
- molecule
- seq
- cpg
- Prior art date
Links
- FBUBJNLRKJPTDA-SMDDNHRTSA-N CC(C)[C@@H](CC[C@H]1CNc2c3cccc2)N1C3=N Chemical compound CC(C)[C@@H](CC[C@H]1CNc2c3cccc2)N1C3=N FBUBJNLRKJPTDA-SMDDNHRTSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Definitions
- This application relates generally to compositions and methods for treating cancers, such as myelodysplasia syndromes (MDS).
- MDS myelodysplasia syndromes
- MDS Myelodysplasia syndromes
- MDS are hematopoietic stem cell malignancies with a rising prevalence owing to the aging of the American population.
- MDS comprise a group of malignant hematologic disorders associated with impaired erythropoiesis, dysregulated myeloid
- MDS myeloid leukemia
- US United States
- LEN lenalidomide
- compositions and methods are disclosed for targeted treatment of cancer or cancer-stem cells expressing a tumor antigen.
- tumor antigen targeting agents such as antibodies or ligands, are conjugated to a cytotoxic agent, e.g. via a bivalent linker.
- the cytotoxic agent is a lytic peptide.
- the molecule comprises an anti-tumor associated antigen (TAA) binding agent conjugated to a lytic peptide, e.g. via a bivalent linker.
- TAA anti-tumor associated antigen
- the lytic peptide comprises the amino acid sequence KAF KKAF KAF KKAF KAF K (SEQ ID NO: 1).
- the lytic peptide function is attributable to the alternating positively and negatively charged amino acids. Therefore, in some embodiments, the lytic peptide comprises the amino acid sequence PHH PPH HPH HPP HHP HHP (SEQ ID NO:2), where P is a positively charged amino acid and H is a hydrophobic amino acid.
- the lytic peptide comprise an amino acid sequence that has at least 65%, 70%, 71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the amino acid sequence SEQ ID NO:2, or a fragment thereof of at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, or 25 amino acids in length.
- compositions and methods are disclosed for targeted treatment of cancer or cancer-stem cells with extracellular toll like receptor-9 (TLR9) expression, such as primary human MDS progenitors, hematopoietic stem cell (HSC), and liver cancers.
- TLR9 expression such as primary human MDS progenitors, hematopoietic stem cell (HSC), and liver cancers.
- the cancer comprises a solid tumor.
- the cancer comprises a myelodysplasia syndrome (MDS).
- MDS myelodysplasia syndrome
- the cancer can be non-del(5q) MDS.
- Figures 4 identifies other cancers, such as lung, liver, and breast cancers, that have increased TLR9 expression.
- Figure 5 shows TLR9 protein expression in a variety of tumor tissues.
- cancers of the skin, esophagus, colon, rectum, liver, lung, and uterus have been shown to have increased TLR9 protein expression.
- the method further involves assaying a biopsy sample from the subject for TLR9 expression prior to treatment.
- molecules containing TLR9 targeting ligands that target lytic peptides to TLR9-expressing malignant cells are disclosed.
- the TLR9 targeting ligand is an unmethylated CpG oligodeoxynucleotide, or an analogue or derivative thereof that binds TLR9.
- CpG oligodeoxynucleotides are short single-stranded synthetic DNA molecules that contain a cytosine triphosphate deoxynucleotide ("C") followed by a guanine triphosphate deoxynucleotide ("G").
- C cytosine triphosphate deoxynucleotide
- G guanine triphosphate deoxynucleotide
- the "p” refers to the phosphodiester link between consecutive nucleotides, although some ODN have a modified phosphorothioate (PS) backbone instead.
- PS modified phosphorothioate
- the core CpG motif which consists of a hexamer with a central unmethylated CpG, has the general formula RRCGYY (where R represents a purine and Y a pyrimidine).
- SAR structure-activity relationship
- the immune- stimulatory activity of an ODN is determined by the number of CpG motifs it contains (usually two to four are optimal), the spacing of the CpG motifs (usually at least two intervening bases, preferably thymine residues, is optimal), the presence of poly-G sequences or other flanking sequences in the ODN (effect depends on ODN structure and backbone), and the ODN backbone (a nuclease-resistant phosphorothioate backbone is the most stable and best for activating B cells, but gives relatively weaker induction of IFNa secretion from pDC compared with native phosphodiester linkages in the CpG dinucleotide).
- the immunestimulatory effects of the ODN are enhanced if there is a TpC dinucleotide on the 5' end and if the ODN is pyrimidine rich on the 3' side.
- Example TLR9 agonist CpG ODNs include CPG 10101 (Coley), ODN 1018 ISS (Dynavax), CPG 7909 (GlaxoSmithKline (GSK)/Coley and DARPA/N I Al D/Coley) , ODN PF-3512676 (Pfizer/Coley), and ODN 1018 ISS (Dynavax).
- the TLR9 ligand comprises the CpG sequence
- the TLR9 ligand comprises the CpG sequence TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID NO:4). In some cases, the TLR9 ligand comprises the CpG sequence TCCATGACGTTCCTGACGTT (SEQ ID NO:5). In some cases, the TLR9 ligand comprises the CpG sequence GGGGACGACGTCGTGGGGGGG (SEQ ID NO:6). In some cases, the TLR9 ligand comprises the CpG sequence
- the TLR9 ligand comprises the CpG sequence TCGTCGTTGTCGTTTTGTCGTT (SEQ ID NO:8). In some cases, the TLR9 ligand comprises the CpG sequence TCGACGTTCGTCGTTCGTCGTTC (SEQ ID NO:9). In some cases, the TLR9 ligand comprises the CpG sequence
- the TLR9 ligand comprises the CpG sequence TCGTCGTTTTCGGCGCGCCG (SEQ ID NO: 1 1). In some cases, the TLR9 ligand comprises the CpG sequence TCGTCGTCGTTCGAACGACGTTGAT (SEQ ID NO: 12). In some cases, the TLR9 ligand comprises the CpG sequence TCGCGAACGTTCGCCGCGTTCGAACGCGG (SEQ ID NO: 13).
- the CpG nucleotides have phosphodiester backbones.
- one or more of the nucleotides have modified phosphorothioate (nuclease resistant) backbones.
- the TLR9 ligand comprises the CpG sequence
- compositions and methods are disclosed for targeted treatment of cancer or cancer-stem cells with extracellular CD33 expression, such as acute myeloid leukemia (AML).
- compositions and methods are disclosed for targeted treatment of cancer or cancer-stem cells with extracellular EGF-R expression, such as lung, head and neck, and many other epithelial cancers.
- compositions and methods are disclosed for targeted treatment of cancer or cancer-stem cells with extracellular HER2 expression, such as breast cancers.
- compositions and methods are disclosed for targeted treatment of cancer or cancer-stem cells with extracellular CD19 expression, such as B-cell Non-Hodgkin Lymphoma (NHL), Chronic lymphocytic leukemia (CLL), and B-cell Acute lymphoblastic leukemia (ALL).
- B-cell Non-Hodgkin Lymphoma NHL
- CLL Chronic lymphocytic leukemia
- ALL B-cell Acute lymphoblastic leukemia
- compositions and methods are disclosed for targeted treatment of cancer or cancer-stem cells with extracellular CD123 expression, such as AML, blastic plasmocytoid dendritic cell neoplasm, hairy cell leukemia, and ALL.
- compositions and methods are disclosed for targeted treatment of cancer or cancer-stem cells with extracellular B-cell maturation antigen (BCMA) expression, such as multiple myeloma.
- BCMA B-cell maturation antigen
- Tumor antigen targeting agents that bind CD33, EGF-R, HER2,
- the bivalent linker is a C6 amino-SMCC-Cys linker.
- the linker is produced using click chemistry reactions.
- the click chemistry approach was originally conceived as a method to rapidly generate complex substances by joining small subunits together in a modular fashion.
- Various forms of click chemistry reaction are known in the art, such as the Huisgen 1 ,3-dipolar cycloaddition copper catalyzed reaction, which is often referred to as the "click reaction.”
- Other alternatives include cycloaddition reactions such as the Diels-Alder, nucieophilsc substitution reactions (especially to small strained rings like epoxy and aziridine compounds), carbony! chemistry formation of urea compounds and reactions involving carbon-carbon double bonds, such as a!kynes in thio!-yne reactions.
- a pharmaceutical composition comprising a molecule disclosed herein in a pharmaceutically acceptable carrier. Also disclosed is a method for treating a cancer, such as a TLR9-positive cancer, in a subject that involves administering to the subject a therapeutically effective amount of a disclosed pharmaceutical composition.
- the cancer of the disclosed methods can be any cell in a subject undergoing unregulated growth, invasion, or metastasis that is expressing tumor antigen, such as TLR9, CD33, EGF-R, HER2, CD19, CD123, and BCMA.
- tumor antigen such as TLR9, CD33, EGF-R, HER2, CD19, CD123, and BCMA.
- the cancer can be a sarcoma, lymphoma, leukemia, carcinoma, blastoma, or germ cell tumor.
- a representative but non-limiting list of cancers include lymphoma, B cell lymphoma, T cell lymphoma, mycosis fungoides, Hodgkin's Disease, myeloid leukemia, bladder cancer, brain cancer, nervous system cancer, head and neck cancer, squamous cell carcinoma of head and neck, kidney cancer, lung cancers such as small cell lung cancer and non-small cell lung cancer, neuroblastoma/glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, squamous cell carcinomas of the mouth, throat, larynx, and lung, colon cancer, cervical cancer, cervical carcinoma, breast cancer, epithelial cancer, renal cancer, genitourinary cancer, pulmonary cancer, esophageal carcinoma, head and neck carcinoma, large bowel cancer, hematopoietic cancers; testicular cancer; colon and rectal cancers, prostatic cancer, and pancreatic cancer.
- the cancer comprises a myelodysplasia syndrome (MDS).
- MDS myelodysplasia syndrome
- the cancer can be non-del(5q) MDS.
- Figures 4 identifies other cancers, such as lung, liver, and breast cancers, that have increased TLR9 expression.
- Figure 5 shows TLR9 protein expression in a variety of tumor tissues. For example, cancers of the skin, esophagous, colon, rectum, liver, lung, and uterus have been shown to have increased TLR9 protein expression.
- the method further involves assaying a biopsy sample from the subject for TLR9 expression prior to treatment.
- Figure 1 shows synthesis path of linkage using Click-IT chemistry.
- Figure 2 shows sequences of a phosphorothioated CpG linked and peptide sequences and C6 amino-SMCC-Cys linker strategy.
- Figure 3 shows example lytic peptide 3D structure and structure of scrambled control used.
- Figure 4 is a box plot showing TLR9 overexpression in a variety of tumors.
- the box plot represents the 25th to 75th percentile (the box) with the median represented by the black line in the box.
- the outliers are in circles represent the median absolute deviation (2 SD is about the same).
- FIG. 5 shows results of tissue microarray (TMA) slides being stained with anti-TLR9 antibody.
- the top graph shows the tabulated data for the cores in the control TMA and a representative picture from one of the cores demonstrating the lack of brown coloration. The only positive core in that slide was inflamed tonsils which serve as a positive control.
- the second graph shows the tabulated results from the multi-tumor TMA (48 cases of 15 cancers) showing varied levels of TLR9 positive staining. The picture represents the core for a melanoma case that had heavy brown staining as a representative figure.
- Figure 6 shows two separate MDS BM primary specimens were treated with CpG conjugated with siRNA targeting BrnaH sequences 1 and 2 (two different sequences) or their combination, cultured for 48 hours before reculturing in methylcellulose media supplemented with growth factors for 14 days. At that point hematopoietic colonies were counted for BFU-E and CFU-GM.
- Figure 7 shows an MDS BM primary specimen was treated with CpG conjugated with siRNA targeting BrnaH sequences 1 and 2 (two different sequences) or their combination, cultured for 48 hours before cytospinning into a slide. Cells were then stained for BrnaH expression and DAPI for nuclear staining. Slides were pictured in a confocal microscope.
- Figure 8 shows three separate MDS BM primary specimens were treated with CpG conjugated with lytic peptide, cultured for 48 hours before reculturing in methylcellulose media supplemented with growth factors for 14 days. At that point hematopoietic colonies were counted for BFU-E and GFU-GM.
- Figures 9A and 9B show CpG-lytic peptide acts effectively at a low dose (Fig. 9A) and with quick sustained response (Fig. 9B) ex vivo in a primary patient bone marrow.
- Figure 9C shows reduction of overexpressing TLR9+ cells in wildtype and S100A9Tg mice without affecting basal levels of normal cells.
- Figure 10 shows the effectiveness of CpG-siRNA constructs (BCL2, BCL-XL and MCL1) using SKM 1 , a cell line derived from an MDS patient which has high surface TLR9 expression.
- Figure 11 shows targeting of BrnaH by CpG-siRNA also reduced the proportion of surface TLR9+ cells in a primary specimen.
- compositions and methods are disclosed for targeted treatment of cancer or cancer-stem cells expressing a tumor associated antigen (TAA), such as toll like receptor-9 (TLR9), CD33, EGF-R, HER2, CD19, CD123, and BCMA.
- TAA tumor associated antigen
- anti-TAA binding agent such as antibodies or ligands, are conjugated to lytic peptides disclosed herein, e.g. using a bivalent linker disclosed herein.
- the anti-TAA binding agent is single chain variable fragment (scFv) antibody.
- the affinity/specificity of an anti-TAA scFv is driven in large part by specific sequences within complementarity determining regions (CDRs) in the heavy (V H ) and light (V L ) chain. Each V H and V L sequence will have three CDRs (CDR1 , CDR2, CDR3).
- the anti-TAA binding agent is an affinity maturated scFv.
- the anti-TAA has a dissociation constant (K D ) for the TAA that is less than 50 nM, 40 nM, 30 nM, 25 nM, 20 nM, 15 nM, or 10 nM.
- the anti-TAA binding agent is derived from natural antibodies, such as monoclonal antibodies.
- the antibody is human.
- the antibody has undergone an alteration to render it less immunogenic when administered to humans.
- the alteration comprises one or more techniques selected from the group consisting of chimerization, humanization, CDR-grafting, deimmunization, and mutation of framework amino acids to correspond to the closest human germline sequence.
- Tumor antigens are proteins that are produced by tumor cells that elicit an immune response, particularly T-cell mediated immune responses.
- the additional antigen binding domain can be an antibody or a natural ligand of the tumor antigen. The selection of the additional antigen binding domain will depend on the particular type of cancer to be treated. Tumor antigens are well known in the art and include, for example, a glioma-associated antigen,
- CEA carcinoembryonic antigen
- EGFRvlll carcinoembryonic antigen
- IL-IIRa IL-13Ra
- EGFR carcinoembryonic antigen
- FAP B7H3, Kit
- CA LX CA LX
- the tumor antigen is selected from the group consisting of folate receptor (FRa), mesothelin, EGFRvlll, IL-13Ra, CD123, CD19, CD33, BCMA, GD2, CLL-1 , CA-IX, MUCI, HER2, and any combination thereof.
- tumor antigens include the following: Differentiation antigens such as tyrosinase, TRP-1 , TRP-2 and tumor-specific multilineage antigens such as MAGE-1 , MAGE-3, BAGE, GAGE-1 , GAGE-2, pi 5; overexpressed embryonic antigens such as CEA;
- tumor-suppressor genes such as p53, Ras, HER-2/neu; unique tumor antigens resulting from chromosomal translocations; such as BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR; and viral antigens, such as the Epstein Barr virus antigens EBVA and the human papillomavirus (HPV) antigens E6 and E7.
- p53 p53
- Ras HER-2/neu
- unique tumor antigens resulting from chromosomal translocations such as BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR
- viral antigens such as the Epstein Barr virus antigens EBVA and the human papillomavirus (HPV) antigens E6 and E7.
- the TAA is TLR9. Therefore, disclosed are compositions and methods for targeting TLR9-expressing cancers, such as primary human MDS hematopoietic stem and progenitor cells (HSPC).
- Figure 4 identifies other cancers, such as lung and breast cancers, that have increased TLR9 expression.
- Figure 5 shows TLR9 protein expression in a variety of tumor tissues. For example, cancers of the skin, esophagus, colon, rectum, liver, lung, and uterus have been shown to have increased TLR9 protein expression.
- the molecule can comprise a TLR9 targeting ligand ("TTL") and a lytic peptide disclosed herein.
- TTL TLR9 targeting ligand
- the TTL and cytotoxic agent can be joined by a bivalent linker.
- the molecule comprises a TTL conjugated to any payload, such as a diagnostic or therapeutic agent, via a bivalent linker disclosed herein.
- payloads include therapeutic and diagnostic agents.
- therapeutic agents include cytotoxic compounds, lytic peptides, cationic toxic lipid moieties, radioactive isotypes, or other chemical compounds.
- the TTL can in some embodiments be a CpG oligodeoxynucleotide, such as an unmethylated CpG oligodeoxynucleotide, or an analogue or derivative thereof that binds TLR9.
- CpG oligodeoxynucleotides (or CpG ODN) are short single-stranded synthetic DNA molecules that contain a cytosine triphosphate deoxynucleotide followed by a guanine triphosphate deoxynucleotide.
- the "p” refers to the phosphodiester link between consecutive nucleotides, although some ODN have a modified phosphorothioate (PS) backbone instead.
- CpG motifs are considered pathogen- associated molecular patterns (PAMPs) due to their abundance in microbial genomes but their rarity in vertebrate genomes.
- the CpG PAMP is recognized by the pattern recognition receptor (PRR) Toll-Like Receptor 9 (TLR9), which is constitutively expressed internally only in B cells and plasmacytoid dendritic cells (pDCs) in humans and other higher primates.
- PRR pattern recognition receptor
- TLR9 Toll-Like Receptor 9
- pDCs plasmacytoid dendritic cells
- MDS progenitors and in particular MDS stem cells (HSC), overexpress Toll-like receptor (TLR)-9 extracellularly, permitting development of a targeting approach using unmethylated CpG oligonucleotides linked to bioactive payloads for cellular delivery.
- HSC MDS stem cells
- TLR Toll-like receptor
- Synthetic CpG ODN differ from microbial DNA in that they have a partially or completely phosphorothioated (PS) backbone instead of the typical phosphodiester backbone and a poly G tail at the 3' end, 5' end, or both.
- PS modification protects the ODN from being degraded by nucleases such as DNase in the body and poly G tail enhances cellular uptake.
- the poly G tails form intermolecular tetrads that result in high molecular weight aggregates. Numerous sequences have been shown to stimulate TLR9 with variations in the number and location of CpG dimers, as well as the precise base sequences flanking the CpG dimers.
- the five classes are Class A (Type D), Class B (Type K), Class C, Class P, and Class S.
- the TTL comprises an antibody.
- antibody refers to natural or synthetic antibodies that selectively bind a target antigen.
- the term includes polyclonal and monoclonal antibodies.
- antibodies are fragments or polymers of those immunoglobulin molecules, and human or humanized versions of immunoglobulin molecules that selectively bind the target antigen.
- Antibodies that can be used in the disclosed compositions and methods include whole immunoglobulin (i.e., an intact antibody) of any class, fragments thereof, and synthetic proteins containing at least the antigen binding variable domain of an antibody.
- the variable domains differ in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not usually evenly distributed through the variable domains of antibodies. It is typically concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of the variable domains are called the framework (FR).
- CDRs complementarity determining regions
- FR framework
- variable domains of native heavy and light chains each comprise four FR regions, largely adopting a beta-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the beta-sheet structure.
- the CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site of antibodies.
- fragments of antibodies which have bioactivity.
- the fragments whether attached to other sequences or not, include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the fragment is not significantly altered or impaired compared to the nonmodified antibody or antibody fragment.
- a single chain antibody can be created by fusing together the variable domains of the heavy and light chains using a short peptide linker, thereby reconstituting an antigen binding site on a single molecule.
- Single-chain antibody variable fragments scFvs
- the linker is chosen to permit the heavy chain and light chain to bind together in their proper conformational orientation.
- Divalent single-chain variable fragments can be engineered by linking two scFvs. This can be done by producing a single peptide chain with two VH and two VL regions, yielding tandem scFvs. ScFvs can also be designed with linker peptides that are too short for the two variable regions to fold together (about five amino acids), forcing scFvs to dimerize. This type is known as diabodies. Diabodies have been shown to have dissociation constants up to 40-fold lower than corresponding scFvs, meaning that they have a much higher affinity to their target. Still shorter linkers (one or two amino acids) lead to the formation of trimers (triabodies or tribodies). Tetrabodies have also been produced. They exhibit an even higher affinity to their targets than diabodies.
- the bivalent linker can be any molecule suitable to link a compound, polypeptide, or nucleic acid to a TTL (e.g., CpG ODN).
- TTL e.g., CpG ODN
- Methods and compositions for conjugating biomolecules, such as polynucleotides, are disclosed in G.T. Hermanon, Bioconjugate Techniques (2 nd ed.), Academic Press (2008), which is incorporated by reference in its entirety for the teaching of these techniques.
- the bivalent linker is a non-nucleotidic linker.
- non-nucleotidic refers to a linker that does not include nucleotides or nucleotide analogs.
- non-nucleotidic linkers comprise an atom such as oxygen or sulfur, a unit such as C(O), C(0)NH, SO, S0 2 , SO 2 NH, or a chain of atoms, such as substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl,
- the bivalent linker comprises at least one cleavable linking group, i.e. the linker is a cleavable linker.
- a "cleavable linker” refers to linkers that are capable of cleavage under various conditions. Conditions suitable for cleavage can include, but are not limited to, pH, UV irradiation, enzymatic activity, temperature, hydrolysis, elimination and substitution reactions, redox reactions, and thermodynamic properties of the linkage.
- a cleavable linker can be used to release the linked components after transport to the desired target. The intended nature of the conjugation or coupling interaction, or the desired biological effect, will determine the choice of linker group.
- the bivalent linker can comprise a photocleavable PC linker.
- the oligonucleotide is cleavable by dicer to produce isolate individual siRNA from the oligonucleotide.
- linkers include Hexanediol, Spacer 9, Spacer 18, 1 ',2'- Dideoxyribose (dSc), and l-Linker.
- the linker comprises m-Maleimidobenzyol-N-hydroxysuccinimide ester (MBS), Sulfo-m-maleimidobenzyol-N-hydroxysuccinimide ester (sulfo-MBS), or
- Sulfosuccinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate SMCC
- the linker is a C6 amino-SMCC-Cys linker as shown in Figure 2.
- the linker is produced using click chemistry reactions, as shown in Figure 1.
- the click chemistry approach was originally conceived as a method to rapidly generate complex substances by joining small subunits together in a modular fashion.
- click chemistry reaction Various forms of click chemistry reaction are known in the art, such as the Hussgen 1 ,3-dipolar cycioaddiiion copper catalyzed reaction, which is often referred to as the "click reaction '
- Other alternatives include cycloaddiiion reactions such as the Diels-A!der, nucleophilic substitution reactions (especially to small strained rings like epoxy and aziridine compounds), carbonyi chemistry formation of urea compounds and reactions involving carbon-carbon double bonds, such as alkynes in thiol-yne reactions.
- the cytotoxic agent of the disclosed compositions can be any agent capable of killing a cancer cell, e.g., when internalized by the cell.
- the cytotoxic agent may be a cytotoxic peptide (e.g., lytic peptide) or a radionuclide.
- Suitable cytotoxins are known to those skilled in the art and include plant and bacterial toxins, such as, abrin, alpha toxin, diphtheria toxin, exotoxin, gelonin, pokeweed antiviral protein, ricin, and saporin.
- Cytolytic peptides are also described as pore-forming peptides or cytolysins. Interactions of pore forming peptides with the surface of the membrane may be based on nonspecific electrostatic interactions of the positively charged peptide with negatively charged surface of cell membrane. These peptides are generally of cationic character, so that they are capable of electrostatic interactions with surfaces with predominantly negatively charged particles.
- a cytolytic peptide Upon contact and interaction of a cytolytic peptide with lipids on the cell surface, and after penetration inside the cell with the lipids on the surface of the mitochondrial membrane, interruption of the continuity of the cell membrane occurs, followed by formation of small size transmembrane pores, by which leakage of the contents of the cytoplasm, including ions, outside the cell occurs, resulting in rapid and irreversible electrolyte imbalance in the cell, cell lysis and death.
- the interactions of pore- forming peptides with the surface of the membrane may also include interactions with specific receptors present on the surface.
- Naturally occurring cytolytic peptides of bacterial, plant or mammalian origin capable of forming pores include cecropin A and B, aurein 1 .2, citropin 1 .1 , defensin (HNP-2), lactoferricin B, tachyplesin, PR-39, cytolysins of Enterococcus faecalis, delta hemolysin, diphtheria toxin, cytolysin of Vibrio cholerae, toxin from Actinia equina, granulysin, lytic peptides from cecropin A and B, aurein 1 .2, citropin 1 .1 , defensin (HNP-2), lactoferricin B, tachyplesin, PR-39, cytolysins of Enterococcus faecalis, delta hemolysin, diphtheria toxin, cytolysin of Vibrio cholerae, toxin from Actinia
- Streptococcus intermedius Streptococcus intermedius, lentiviral lytic peptides, leukotoxin of Actinobacillus
- actinomycetemcomitans magainin, melittin, lymphotoxin, enkephalin, paradaxin, perforin (in particular the N-terminal fragment thereof), perfringolysin 0 (PFO/theta toxin) from Clostridium perfringens, and streptolysins.
- cytolytic pore-forming peptides There are also known synthetic cytolytic pore-forming peptides. They are often hybrids of natural cytolytic peptides fragments, such as a hybrid of a cecropin A fragment and a magainin 2 fragment or a hybrid of a cecropin A fragment and a melittin fragment. Other well-known cytolytic synthetic peptides are described, for example, in Regen et al., Biochem. Biophys. Res. Commun. (199) 159:566-571 , which is incorporated by reference for these peptides.
- the lytic peptide comprises the amino acid sequence
- the lytic peptide function is attributable to the alternating positively and negatively charged amino acids. Therefore, in some embodiments, the lytic peptide comprises the amino acid sequence PHHPPHHPHHPPHHPHHP (SEQ ID NO:2), where P is a positively charged amino acid and H is a hydrophobic amino acid.
- the lytic peptide comprise an amino acid sequence that has at least 65%, 70%, 71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the amino acid sequence SEQ ID NO:2, or a fragment thereof of at least 12, 13, 14, 15, 16, or 17 amino acids in length.
- the lytic peptide comprises an amino acid sequence selected from the group consisting of KIKMVISWKG (SEQ ID NO: 18; HYD1); AIAMVISWAG (SEQ ID NO: 19; HYD8); AIKMVISWAG (SEQ ID NO:20; HYD6); AIKMVISWKG (SEQ ID NO:21 ; HYD2);
- AKMVISW (SEQ ID NO:22); AKMVISWKG (SEQ ID NO:23); IAMVISW (SEQ ID NO:24);
- IAMVISWKG (SEQ ID NO:25); IKAVISW (SEQ ID NO:26); IKAVISWKG (SEQ ID NO: 27);
- IKMAISW (SEQ ID NO:28); IKMAISWKG (SEQ ID NO:29); IKMVASW (SEQ ID NO:30);
- IKMVASWKG SEQ ID NO:31
- IKMVIAW SEQ ID NO:32
- IKMVIAWKG SEQ ID NO:33
- IKMVISA SEQ ID NO:34
- IKMVISAKG SEQ ID NO:35
- IKMVISW SEQ ID NO:36
- IKMVISWAG (SEQ ID NO:37); KMVISWKA (SEQ ID NO:38); IKMVISWKG (SEQ ID NO:39; HYDI 8; (-K)HYDI); ISWKG (SEQ ID NO:40); KAKMVISWKG (SEQ ID NO:41); KIAMVISWAG (SEQ ID NO:42; HYD7); KIAMVISWKG (SEQ ID NO:43); KIKAVISWKG (SEQ ID NO:44); KIKMAISWKG (SEQ ID NO:45); KIKMV (SEQ ID NO:46); KIKMVASWKG (SEQ ID NO:47); KIKMVI (SEQ ID NO:48; HYDI 6); KIKMVIA WKG (SEQ ID NO:49); KIKMVIS (SEQ ID NO:50; HYDI 5);
- KIKMVISAKG SEQ ID NO:51
- KIKMVISW SEQ ID NO:52; HYD14
- KIKMVISWAG SEQ ID NO:53
- KIKMVISWK SEQ ID NO:54; HYD17; HYDI(-G)
- KIKMVISWKA SEQ ID NO:55
- KMVISWKG (SEQ ID NO:56; HYD9); LSWKG (SEQ ID NO:57; HYD12); MVISWKG (SEQ ID NO:58; HYDIO); SWKG (SEQ ID NO:59; HYD13); VISWKG (SEQ ID NO:60; HYDI I);
- WIKSMKIVKG SEQ ID NO:61
- KMVIXW SEQ ID NO:62
- IKMVISWXX SEQ ID NO:63
- KMVISWXX SEQ ID NO:64
- X is any amino acid (traditional or non-traditional amino acid).
- the peptide consists of the identified amino acid sequence.
- the peptide consists essentially of the identified amino acid sequence.
- the lytic peptide can comprise at least one D-amino acid. In some cases, each amino acid of the peptide is a D-amino acid.
- the cytotoxic agent is a pyrrolobenzodiazepine (PBD).
- PBDs Pyrrolobenzodiazepines
- the cytotoxic agent is a functional nucleic acid, such as one that inhibits anti-apoptotic gene targets (e.g., Bcl-2, Bcl-xL, and Mcl-1), or promotes apoptotic gene targets (e.g., Bax, Bak, and Bcl-xS).
- anti-apoptotic gene targets e.g., Bcl-2, Bcl-xL, and Mcl-1
- promotes apoptotic gene targets e.g., Bax, Bak, and Bcl-xS.
- Functional nucleic acid molecules can be divided into the following categories, which are not meant to be limiting.
- functional nucleic acids include antisense molecules, aptamers, ribozymes, triplex forming molecules, RNAi, and external guide sequences.
- the functional nucleic acid molecules can act as affectors, inhibitors, modulators, and stimulators of a specific activity possessed by a target molecule, or the functional nucleic acid molecules can possess a de novo activity independent of any other molecules.
- Functional nucleic acid molecules can interact with any macromolecule, such as DNA, RNA, polypeptides, or carbohydrate chains. Often functional nucleic acids are designed to interact with other nucleic acids based on sequence homology between the target molecule and the functional nucleic acid molecule. In other situations, the specific recognition between the functional nucleic acid molecule and the target molecule is not based on sequence homology between the functional nucleic acid molecule and the target molecule, but rather is based on the formation of tertiary structure that allows specific recognition to take place.
- Antisense molecules are designed to interact with a target nucleic acid molecule through either canonical or non-canonical base pairing.
- the interaction of the antisense molecule and the target molecule is designed to promote the destruction of the target molecule through, for example, RNAseH mediated RNA-DNA hybrid degradation.
- the antisense molecule is designed to interrupt a processing function that normally would take place on the target molecule, such as transcription or replication.
- Antisense molecules can be designed based on the sequence of the target molecule. Numerous methods for optimization of antisense efficiency by finding the most accessible regions of the target molecule exist. Exemplary methods would be in vitro selection experiments and DNA modification studies using DMS and DEPC.
- antisense molecules bind the target molecule with a dissociation constant (K d ) less than or equal to 10 "6 , 10 "8 , 10 "10 , or 10 "12 .
- K d dissociation constant
- Aptamers are molecules that interact with a target molecule, preferably in a specific way.
- aptamers are small nucleic acids ranging from 15-50 bases in length that fold into defined secondary and tertiary structures, such as stem-loops or G-quartets.
- Aptamers can bind small molecules, such as ATP (U.S. Patent No. 5,631 ,146) and theophiline (U.S. Patent No. 5,580,737), as well as large molecules, such as reverse transcriptase (U.S. Patent No. 5,786,462) and thrombin (United States patent 5,543,293).
- Aptamers can bind very tightly with K d 's from the target molecule of less than 10 "12 M.
- the aptamers bind the target molecule with a Kd less than 10 "6 , 10 "8 , 10 "10 , or 10 "12 .
- Aptamers can bind the target molecule with a very high degree of specificity.
- aptamers have been isolated that have greater than a 10,000 fold difference in binding affinities between the target molecule and another molecule that differ at only a single position on the molecule (U.S. Patent No. 5,543,293).
- the aptamer have a K d with the target molecule at least 10, 100, 1000, 10,000, or 100,000 fold lower than the K d with a background binding molecule.
- the background molecule be a different polypeptide.
- Representative examples of how to make and use aptamers to bind a variety of different target molecules can be found in U.S. Patent Nos. 5,476,766, 5,503,978, 5,631 ,146, 5,731 ,424 , 5,780,228, 5,792,613, 5,795,721 , 5,846,713, 5,858,660 , 5,861 ,254, 5,864,026, 5,869,641 , 5,958,691 , 6,001 ,988, 6,01 1 ,020, 6,013,443, 6,020, 130, 6,028,186, 6,030,776, and 6,051 ,698.
- Ribozymes are nucleic acid molecules that are capable of catalyzing a chemical reaction, either intramolecularly or intermolecularly. Ribozymes are thus catalytic nucleic acid. It is preferred that the ribozymes catalyze intermolecular reactions.
- ribozymes There are a number of different types of ribozymes that catalyze nuclease or nucleic acid polymerase type reactions which are based on ribozymes found in natural systems, such as hammerhead ribozymes, (U.S. Patent Nos.
- ribozymes that are not found in natural systems, but which have been engineered to catalyze specific reactions de novo (for example, U.S. Patent Nos. 5,580,967, 5,688,670, 5,807,718, and 5,910,408).
- Preferred ribozymes cleave RNA or DNA substrates, and more preferably cleave RNA substrates.
- Ribozymes typically cleave nucleic acid substrates through recognition and binding of the target substrate with subsequent cleavage.
- Triplex forming functional nucleic acid molecules are molecules that can interact with either double-stranded or single-stranded nucleic acid.
- triplex molecules When triplex molecules interact with a target region, a structure called a triplex is formed, in which there are three strands of DNA forming a complex dependant on both Watson-Crick and Hoogsteen base-pairing. Triplex molecules are preferred because they can bind target regions with high affinity and specificity. It is preferred that the triplex forming molecules bind the target molecule with a K d less than 10 "6 , 10 "8 , 10 "10 , or 10 "12 . Representative examples of how to make and use triplex forming molecules to bind a variety of different target molecules can be found in U.S. Patent Nos. 5, 176,996, 5,645,985, 5,650,316, 5,683,874, 5,693,773, 5,834, 185, 5,869,246, 5,874,566, and 5,962,426.
- EGSs External guide sequences
- RNase P RNase P
- EGSs can be designed to specifically target a RNA molecule of choice.
- RNAse P aids in processing transfer RNA (tRNA) within a cell.
- Bacterial RNAse P can be recruited to cleave virtually any RNA sequence by using an EGS that causes the target RNA:EGS complex to mimic the natural tRNA substrate. (WO 92/03566 by Yale, and Forster and Altman, Science 238:407- 409 (1990)).
- RNAse P-directed cleavage of RNA can be utilized to cleave desired targets within eukarotic cells.
- WO 93/22434 by Yale
- WO 95/24489 by Yale
- Yuan and Altman EMBO J 14: 159-168 (1995)
- Carrara et al. Proc. Natl. Acad. Sci. (USA) 92:2627-2631 (1995)
- Representative examples of how to make and use EGS molecules to facilitate cleavage of a variety of different target molecules be found in U.S. Patent Nos. 5, 168,053, 5,624,824, 5,683,873, 5,728,521 , 5,869,248, and 5,877, 162.
- RNAi RNA interference
- dsRNA double stranded RNA
- dsRNA double stranded small interfering RNAs 21 -23 nucleotides in length that contains 2 nucleotide overhangs on the 3' ends
- siRNA double stranded small interfering RNAs
- RISC RNAi induced silencing complex
- Short Interfering RNA is a double-stranded RNA that can induce sequence- specific post-transcriptional gene silencing, thereby decreasing or even inhibiting gene expression.
- an siRNA triggers the specific degradation of homologous RNA molecules, such as mRNAs, within the region of sequence identity between both the siRNA and the target RNA.
- WO 02/44321 discloses siRNAs capable of sequence-specific degradation of target mRNAs when base-paired with 3' overhanging ends, herein incorporated by reference for the method of making these siRNAs.
- Sequence specific gene silencing can be achieved in mammalian cells using synthetic, short double-stranded RNAs that mimic the siRNAs produced by the enzyme dicer (Elbashir, S.M., et al. (2001) Nature, 41 1 :494 498) (Ui-Tei, K., et al. (2000) FEBS Lett 479:79-82).
- siRNA can be chemically or in vitro-synthesized or can be the result of short double-stranded hairpin-like RNAs (shRNAs) that are processed into siRNAs inside the cell.
- Synthetic siRNAs are generally designed using algorithms and a conventional DNA/RNA synthesizer.
- siRNA can also be synthesized in vitro using kits such as Ambion's SILENCER® siRNA Construction Kit. Disclosed herein are any siRNA designed as described above based on the sequences for anti-apoptotic Bcl-2 member proteins, e.g., Bcl-2, Bcl-xL, and Mcl-1 .
- siRNA from a vector is more commonly done through the transcription of a short hairpin RNAs (shRNAs).
- Kits for the production of vectors comprising shRNA are available, such as, for example, Imgenex's GENESUPPRESSORTM Construction Kits and Invitrogen's BLOCK-ITTM inducible RNAi plasmid and lentivirus vectors.
- Disclosed herein are any shRNA designed as described above based on the sequences for the herein disclosed inflammatory mediators.
- the disclosed molecule comprises a plurality of cytotoxic agents linked to each targeting agent.
- the molecule can comprise 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more cytotoxic agents linked directly or indirectly to the targeting agent.
- a pharmaceutical composition comprising a molecule disclosed herein in a pharmaceutically acceptable carrier.
- Pharmaceutical carriers are known to those skilled in the art. These most typically would be standard carriers for administration of drugs to humans, including solutions such as sterile water, saline, and buffered solutions at physiological pH. For example, suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy (21 ed.) ed. PP. Gerbino, Lippincott Williams & Wilkins, Philadelphia, PA. 2005. Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically-acceptable carrier include, but are not limited to, saline, Ringer's solution and dextrose solution.
- the pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5.
- the solution should be RNAse free.
- Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of composition being administered.
- compositions may include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice.
- compositions may also include one or more active ingredients such as antimicrobial agents, anti-inflammatory agents, anesthetics, and the like.
- Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- Parenteral vehicles include sodium chloride solution,
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
- compositions may potentially be administered as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.
- inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid
- organic acids such as formic acid, acetic acid, propionic acid, glyco
- FIG. 4 identifies other cancers, such as lung and breast cancers, that have increased TLR9 expression.
- Figure 5 shows TLR9 protein expression in a variety of tumor tissues. For example, cancers of the skin, esophagus, colon, rectum, liver, lung, and uterus have been shown to have increased TLR9 protein expression.
- a representative but non-limiting list of cancers include lymphoma, B cell lymphoma, T cell lymphoma, mycosis fungoides, Hodgkin's Disease, myeloid leukemia, bladder cancer, brain cancer, nervous system cancer, head and neck cancer, squamous cell carcinoma of head and neck, kidney cancer, lung cancers such as small cell lung cancer and non-small cell lung cancer, neuroblastoma/glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, squamous cell carcinomas of the mouth, throat, larynx, and lung, colon cancer, cervical cancer, cervical carcinoma, breast cancer, epithelial cancer, renal cancer, genitourinary cancer, pulmonary cancer, esophageal carcinoma, head and neck carcinoma, large bowel cancer, hematopoietic cancers; testicular cancer; colon and rectal cancers, prostatic cancer, and pancreatic cancer.
- the method further involves assaying a biopsy sample from the subject for TLR9 expression prior to treatment. This can be done using routine methods, such as
- immunodetection methods Many types and formats of immunoassays are known and all are suitable for detecting the disclosed biomarkers. Examples of immunoassays are enzyme linked immunosorbent assays (ELISAs), radioimmunoassays (RIA), radioimmune precipitation assays (RIPA), immunobead capture assays, Western blotting, dot blotting, gel-shift assays, Flow cytometry, protein arrays, multiplexed bead arrays, magnetic capture, in vivo imaging, fluorescence resonance energy transfer (FRET), and fluorescence recovery/localization after photobleaching (FRAP/ FLAP).
- ELISAs enzyme linked immunosorbent assays
- RIA radioimmunoassays
- RIPA radioimmune precipitation assays
- immunobead capture assays Western blotting
- dot blotting dot blotting
- gel-shift assays Flow cytometry
- protein arrays multiplexed bead array
- compositions including pharmaceutical composition, may be administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated.
- the disclosed compositions can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.
- compositions may be administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, transdermally, extracorporeal ⁇ , ophthalmically, vaginally, rectally, intranasally, topically or the like, including topical intranasal administration or
- Parenteral administration of the composition is generally characterized by injection.
- Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions.
- a revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained.
- compositions disclosed herein may be administered prophylactically to patients or subjects who are at risk for a cancer expressing a disclosed tumor antigen, such as a TLR9- expressing cancer.
- the method can further comprise identifying a subject at risk for the cancer, such as a TLR9-expressing cancer, prior to administration of the herein disclosed compositions.
- compositions required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity of the allergic disorder being treated, the particular nucleic acid or vector used, its mode of
- compositions are those large enough to produce the desired effect in which the symptoms disorder are affected.
- the dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like.
- the dosage will vary with the age, condition, sex and extent of the disease in the patient, route of administration, or whether other drugs are included in the regimen, and can be determined by one of skill in the art.
- the dosage can be adjusted by the individual physician in the event of any contraindications.
- Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days.
- Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products.
- a typical daily dosage of the disclosed composition used alone might range from about 1 ⁇ g/kg to up to 100 mg/kg of body weight or more per day, depending on the factors mentioned above.
- the molecule is administered in a dose equivalent to parenteral administration of about 0.1 ng to about 100 g per kg of body weight, about 10 ng to about 50 g per kg of body weight, about 100 ng to about 1 g per kg of body weight, from about 1 ⁇ g to about 100 mg per kg of body weight, from about 1 ⁇ g to about 50 mg per kg of body weight, from about 1 mg to about 500 mg per kg of body weight; and from about 1 mg to about 50 mg per kg of body weight.
- the amount of molecule administered to achieve a therapeutic effective dose is about 0.1 ng, 1 ng, 10 ng, 100 ng, 1 ⁇ , 10 ⁇ g, 100 ⁇ g, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 1 1 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 500 mg per kg of body weight or greater.
- carrier means a compound, composition, substance, or structure that, when in combination with a compound or composition, aids or facilitates preparation, storage,
- a carrier can be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject.
- CpG motif refers to a nucleotide sequence, which contains unmethylated cytosine-guanine dinucleotide linked by a phosphate bond.
- CpG oligodeoxynucleotide or “CpG ODN” refers to an oligodeoxynucleotide comprising at least one CpG motif and that binds TLR9.
- a “fusion protein” or “fusion polypeptide” refers to a hybrid polypeptide which comprises polypeptide portions from at least two different polypeptides. The portions may be from proteins of the same organism, in which case the fusion protein is said to be "intraspecies", “intragenic", etc.
- the fusion polypeptide may comprise one or more amino acid sequences linked to a first polypeptide. In the case where more than one amino acid sequence is fused to a first polypeptide, the fusion sequences may be multiple copies of the same sequence, or alternatively, may be different amino acid sequences.
- a first polypeptide may be fused to the N-terminus, the C-terminus, or the N- and C-terminus of a second polypeptide. Furthermore, a first polypeptide may be inserted within the sequence of a second polypeptide.
- Gene construct refers to a nucleic acid, such as a vector, plasmid, viral genome or the like which includes a "coding sequence” for a polypeptide or which is otherwise transcribable to a biologically active RNA (e.g., antisense, decoy, ribozyme, etc), may be transfected into cells, e.g. in certain embodiments mammalian cells, and may cause expression of the coding sequence in cells transfected with the construct.
- the gene construct may include one or more regulatory elements operably linked to the coding sequence, as well as intronic sequences, polyadenylation sites, origins of replication, marker genes, etc.
- isolated polypeptide refers to a polypeptide, which may be prepared from recombinant DNA or RNA, or be of synthetic origin, some combination thereof, or which may be a naturally-occurring polypeptide, which (1) is not associated with proteins with which it is normally associated in nature, (2) is isolated from the cell in which it normally occurs, (3) is essentially free of other proteins from the same cellular source, (4) is expressed by a cell from a different species, or (5) does not occur in nature.
- isolated nucleic acid refers to a polynucleotide of genomic, cDNA, synthetic, or natural origin or some combination thereof, which (1) is not associated with the cell in which the "isolated nucleic acid” is found in nature, or (2) is operably linked to a polynucleotide to which it is not linked in nature.
- linker is art-recognized and refers to a molecule or group of molecules connecting two compounds, such as two polypeptides.
- the linker may be comprised of a single linking molecule or may comprise a linking molecule and a spacer molecule, intended to separate the linking molecule and a compound by a specific distance.
- nucleic acid refers to a polymeric form of nucleotides, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide.
- the terms should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single-stranded (such as sense or antisense) and double-stranded polynucleotides.
- pharmaceutically acceptable refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.
- protein if single-chain
- polypeptide if single-chain
- peptide a protein
- a “protein” may also refer to an association of one or more polypeptides.
- gene product is meant a molecule that is produced as a result of transcription of a gene. Gene products include RNA molecules transcribed from a gene, as well as proteins translated from such transcripts.
- polypeptide fragment when used in reference to a particular polypeptide, refers to a polypeptide in which amino acid residues are deleted as compared to the reference polypeptide itself, but where the remaining amino acid sequence is usually identical to that of the reference polypeptide. Such deletions may occur at the amino-terminus or carboxy- terminus of the reference polypeptide, or alternatively both. Fragments typically are at least about 5, 6, 8 or 10 amino acids long, at least about 14 amino acids long, at least about 20, 30, 40 or 50 amino acids long, at least about 75 amino acids long, or at least about 100, 150, 200, 300, 500 or more amino acids long. A fragment can retain one or more of the biological activities of the reference polypeptide. In various embodiments, a fragment may comprise an enzymatic activity and/or an interaction site of the reference polypeptide. In another embodiment, a fragment may have immunogenic properties.
- specifically deliver refers to the preferential association of a molecule with a cell or tissue bearing a particular target molecule or marker and not to cells or tissues lacking that target molecule. It is, of course, recognized that a certain degree of non-specific interaction may occur between a molecule and a non- target cell or tissue. Nevertheless, specific delivery, may be distinguished as mediated through specific recognition of the target molecule. Typically specific delivery results in a much stronger association between the delivered molecule and cells bearing the target molecule than between the delivered molecule and cells lacking the target molecule.
- subject refers to any individual who is the target of administration or treatment.
- the subject can be a vertebrate, for example, a mammal.
- the subject can be a human or veterinary patient.
- patient refers to a subject under the treatment of a clinician, e.g., physician.
- terapéuticaally effective refers to the amount of the composition used is of sufficient quantity to ameliorate one or more causes or symptoms of a disease or disorder. Such amelioration only requires a reduction or alteration, not necessarily elimination.
- treatment refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder.
- This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder.
- this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
- CpG a cognate danger-associated molecular pattern (DAMP) recognized by TLR9, was used as a target for internalization of an amphipatic lytic peptide capable of lysis only when internalized. This allows the targeted killing of malignant TLR9+ hematopoietic stem cells in cancer.
- DAMP danger-associated molecular pattern
- the initial attempt was by linking the CpG and the lytic peptide through the use of a Click-It reaction as demonstrated in Figure 1 .
- this reaction might be less stable, even though the initial reaction performed with CpG-lytic prepared this way has already shown effectivity in reducing TLR9+ stem cells.
- the second strategy involved the use of a C6 amino-SMCC-Cys linker as shown in Figure 2.
- the CpG sequence is fully phosphothioated in order to increase stability of the CpG moiety.
- Figure 2 also shows the sequence of a new lytic peptide and a scrambled sequence that was used as control.
- sequence itself is important, because of the amphitatic nature of the residues, but its main function relies on the helical conformation of the peptide.
- Figure 3 the same sequence of peptides was used but was looped through a 3D structure predictor until a scrambled sequence was found were the helical structure was disrupted.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2019001364A MX2019001364A (en) | 2016-08-03 | 2017-08-02 | Tlr9 targeted therapeutics. |
EP17837618.2A EP3496736A4 (en) | 2016-08-03 | 2017-08-02 | Tlr9 targeted therapeutics |
US16/319,935 US11123435B2 (en) | 2016-08-03 | 2017-08-02 | TLR9 targeted therapeutics |
CN201780059647.3A CN110087665A (en) | 2016-08-03 | 2017-08-02 | TLR9 targeted therapy |
CA3032320A CA3032320A1 (en) | 2016-08-03 | 2017-08-02 | Tlr9 targeted therapeutics |
AU2017306422A AU2017306422A1 (en) | 2016-08-03 | 2017-08-02 | TLR9 targeted therapeutics |
JP2019506177A JP2019524787A (en) | 2016-08-03 | 2017-08-02 | TLR9 targeted therapeutics |
KR1020197005520A KR20190037273A (en) | 2016-08-03 | 2017-08-02 | TLR9 target therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662370428P | 2016-08-03 | 2016-08-03 | |
US62/370,428 | 2016-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018026943A1 true WO2018026943A1 (en) | 2018-02-08 |
Family
ID=61073153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/045140 WO2018026943A1 (en) | 2016-08-03 | 2017-08-02 | Tlr9 targeted therapeutics |
Country Status (9)
Country | Link |
---|---|
US (1) | US11123435B2 (en) |
EP (1) | EP3496736A4 (en) |
JP (1) | JP2019524787A (en) |
KR (1) | KR20190037273A (en) |
CN (1) | CN110087665A (en) |
AU (1) | AU2017306422A1 (en) |
CA (1) | CA3032320A1 (en) |
MX (1) | MX2019001364A (en) |
WO (1) | WO2018026943A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020102382A1 (en) * | 2018-11-13 | 2020-05-22 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Tlr9-targeted therapeutics |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111150842B (en) * | 2019-12-31 | 2023-09-05 | 优锐生物医药科技(深圳)有限公司 | Active immune regulation particle for neutralizing gastrin, and preparation method and application thereof |
CN111150841B (en) * | 2019-12-31 | 2023-08-15 | 优锐生物医药科技(深圳)有限公司 | Active immune regulation particle and preparation method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130012437A1 (en) * | 2011-07-07 | 2013-01-10 | Tuskegee University | Lytic peptides having anti-proliferative activity against prostate cancer cells |
US20140127241A1 (en) * | 2012-10-30 | 2014-05-08 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
US20150343078A1 (en) * | 2013-01-18 | 2015-12-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | TARGETED SENSITIZATION OF NON-DEL(5q) MALIGNANT CELLS |
WO2016070045A1 (en) * | 2014-10-31 | 2016-05-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tlr9 targeted cytotoxic agents |
WO2016070014A1 (en) * | 2014-10-31 | 2016-05-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tetravalent tlr9 bispecific antibody |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834185A (en) | 1986-10-28 | 1998-11-10 | Johns Hopkins University | Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers which comprise pyrimidine analogs, triple helix complexes formed thereby and oligomers used in their formation |
US5294533A (en) | 1988-07-05 | 1994-03-15 | Baylor College Of Medicine | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria |
US5866701A (en) | 1988-09-20 | 1999-02-02 | The Board Of Regents For Northern Illinois University Of Dekalb | HIV targeted hairpin ribozymes |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5624824A (en) | 1989-03-24 | 1997-04-29 | Yale University | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence |
US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
JP2507895B2 (en) | 1989-12-19 | 1996-06-19 | 工業技術院長 | New synthesis system of ribozyme |
US5780228A (en) | 1990-06-11 | 1998-07-14 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands to lectins |
US5723289A (en) | 1990-06-11 | 1998-03-03 | Nexstar Pharmaceuticals, Inc. | Parallel selex |
US5476766A (en) | 1990-06-11 | 1995-12-19 | Nexstar Pharmaceuticals, Inc. | Ligands of thrombin |
US5795721A (en) | 1990-06-11 | 1998-08-18 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of ICP4 |
US6030776A (en) | 1990-06-11 | 2000-02-29 | Nexstar Pharmaceuticals, Inc. | Parallel SELEX |
US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
US6001988A (en) | 1990-06-11 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands to lectins |
US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
US5543293A (en) | 1990-06-11 | 1996-08-06 | Nexstar Pharmaceuticals, Inc. | DNA ligands of thrombin |
US5846713A (en) | 1990-06-11 | 1998-12-08 | Nexstar Pharmaceuticals, Inc. | High affinity HKGF nucleic acid ligands and inhibitors |
US5861254A (en) | 1997-01-31 | 1999-01-19 | Nexstar Pharmaceuticals, Inc. | Flow cell SELEX |
US5869641A (en) | 1990-06-11 | 1999-02-09 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of CD4 |
US5864026A (en) | 1990-06-11 | 1999-01-26 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
US5731424A (en) | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
US5135917A (en) | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
US5271941A (en) | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
US5683874A (en) | 1991-03-27 | 1997-11-04 | Research Corporation Technologies, Inc. | Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence |
US6028186A (en) | 1991-06-10 | 2000-02-22 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of cytokines |
DE4216134A1 (en) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | SYNTHETIC CATALYTIC OLIGONUCLEOTIDE STRUCTURES |
EP0637965B1 (en) | 1991-11-26 | 2002-10-16 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
WO1993022434A2 (en) | 1992-04-28 | 1993-11-11 | Yale University | Targeted cleavage of rna using eukaryotic ribonuclease p and external guide sequence |
US5693535A (en) | 1992-05-14 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | HIV targeted ribozymes |
US5989906A (en) | 1992-05-14 | 1999-11-23 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting P-glycoprotein (mdr-1-gene) |
US5646020A (en) | 1992-05-14 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | Hammerhead ribozymes for preferred targets |
US6017756A (en) | 1992-05-14 | 2000-01-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting hepatitis B virus replication |
US5610054A (en) | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
US5972699A (en) | 1992-05-14 | 1999-10-26 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting herpes simplex virus replication |
CA2139411A1 (en) | 1992-07-02 | 1994-01-20 | Eiko Otsuka | Ribozyme having a thermodynamically stable loop |
US5646042A (en) | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
US5891684A (en) | 1992-10-15 | 1999-04-06 | Ribozyme Pharmaceuticals, Inc. | Base-modified enzymatic nucleic acid |
US5612215A (en) | 1992-12-07 | 1997-03-18 | Ribozyme Pharmaceuticals, Inc. | Stromelysin targeted ribozymes |
US5811300A (en) | 1992-12-07 | 1998-09-22 | Ribozyme Pharmaceuticals, Inc. | TNF-α ribozymes |
WO1994016105A1 (en) | 1993-01-15 | 1994-07-21 | The Public Health Research Institute Of The City Of New York, Inc. | Rna assays using rna binary probes and ribozyme ligase |
US5786138A (en) | 1993-01-29 | 1998-07-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Hyperstabilizing antisense nucleic acid binding agents |
WO1994029444A1 (en) | 1993-06-04 | 1994-12-22 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for treating kaposi's sarcoma with antisense oligonucleotides |
US5962426A (en) | 1993-06-25 | 1999-10-05 | Yale University | Triple-helix forming oligonucleotides for targeted mutagenesis |
EP1253199A1 (en) | 1993-09-02 | 2002-10-30 | Ribozyme Pharmaceuticals, Inc. | Abasic moieties containing enzymatic nucleic acids |
US5861288A (en) | 1993-10-18 | 1999-01-19 | Ribozyme Pharmaceuticals, Inc. | Catalytic DNA |
US5616466A (en) | 1993-11-05 | 1997-04-01 | Cantor; Glenn H. | Ribozyme-mediated inhibition of bovine leukemia virus |
US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
US5712384A (en) | 1994-01-05 | 1998-01-27 | Gene Shears Pty Ltd. | Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
US5641754A (en) | 1994-01-10 | 1997-06-24 | The Board Of Regents Of The University Of Nebraska | Antisense oligonucleotide compositions for selectively killing cancer cells |
US5639647A (en) | 1994-03-29 | 1997-06-17 | Ribozyme Pharmaceuticals, Inc. | 2'-deoxy-2'alkylnucleotide containing nucleic acid |
US5631359A (en) | 1994-10-11 | 1997-05-20 | Ribozyme Pharmaceuticals, Inc. | Hairpin ribozymes |
US5869248A (en) | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
US5595873A (en) | 1994-05-13 | 1997-01-21 | The Scripps Research Institute | T. thermophila group I introns that cleave amide bonds |
US5580967A (en) | 1994-05-13 | 1996-12-03 | The Scripps Research Institute | Optimized catalytic DNA-cleaving ribozymes |
US5683902A (en) | 1994-05-13 | 1997-11-04 | Northern Illinois University | Human papilloma virus inhibition by a hairpin ribozyme |
US5650316A (en) | 1994-06-06 | 1997-07-22 | Research Development Foundation | Uses of triplex forming oligonucleotides for the treatment of human diseases |
US5998193A (en) | 1994-06-24 | 1999-12-07 | Gene Shears Pty., Ltd. | Ribozymes with optimized hybridizing arms, stems, and loops, tRNA embedded ribozymes and compositions thereof |
US5633133A (en) | 1994-07-14 | 1997-05-27 | Long; David M. | Ligation with hammerhead ribozymes |
JPH10503934A (en) | 1994-08-09 | 1998-04-14 | ノバルティス アクチエンゲゼルシャフト | Antitumor antisense oligonucleotide |
US5688670A (en) | 1994-09-01 | 1997-11-18 | The General Hospital Corporation | Self-modifying RNA molecules and methods of making |
AU7954794A (en) | 1994-09-12 | 1996-03-29 | City Of Hope | Modulation of drug radiation resistant genes |
US5599706A (en) | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
US5856103A (en) | 1994-10-07 | 1999-01-05 | Board Of Regents The University Of Texas | Method for selectively ranking sequences for antisense targeting |
JPH08113591A (en) | 1994-10-14 | 1996-05-07 | Taiho Yakuhin Kogyo Kk | Oligonucleotide and carcinostatic agent containing the same as active ingredient |
US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
US5683873A (en) | 1995-01-13 | 1997-11-04 | Innovir Laboratories, Inc. | EGS-mediated inactivation of target RNA |
US5631146A (en) | 1995-01-19 | 1997-05-20 | The General Hospital Corporation | DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof |
US5994320A (en) | 1995-02-06 | 1999-11-30 | Regents Of The University Of Minnesota | Antisense oligonucleotides and methods for treating central nervous system tumors |
IT1275862B1 (en) | 1995-03-03 | 1997-10-24 | Consiglio Nazionale Ricerche | ANTI-SENSE TRANSCRIPT ASSOCIATED WITH SOME TYPES OF TUMOR CELLS AND SYNTHETIC OLIGODEOXYNUCLEOTIDES USEFUL IN DIAGNOSIS AND TREATMENT |
US5770715A (en) | 1995-03-22 | 1998-06-23 | Toagosei Co., Ltd. | Hammerhead-like nucleic acid analogues and their synthesis |
US6013443A (en) | 1995-05-03 | 2000-01-11 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
US5646031A (en) | 1995-05-16 | 1997-07-08 | Northern Illinois University | SArMV and sCYMVI hairpin ribozymes |
US6040296A (en) | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
US5693773A (en) | 1995-06-07 | 1997-12-02 | Hybridon Incorporated | Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines |
EP0833944B1 (en) | 1995-06-07 | 2009-01-07 | Gilead Sciences, Inc. | Nucleic acid ligands that bind to and inhibit dna polymerases |
US5910408A (en) | 1995-06-07 | 1999-06-08 | The General Hospital Corporation | Catalytic DNA having ligase activity |
US5877021A (en) | 1995-07-07 | 1999-03-02 | Ribozyme Pharmaceuticals, Inc. | B7-1 targeted ribozymes |
NO953680D0 (en) | 1995-09-18 | 1995-09-18 | Hans Prydz | Cell cycle Enzymes |
WO1997014709A1 (en) | 1995-10-13 | 1997-04-24 | F. Hoffmann-La Roche Ag | Antisense oligomers |
EP0866865B1 (en) | 1995-11-14 | 2002-02-06 | Vimrx Holdings, Ltd. | Chimeric oligomers having an rna-cleavage activity |
KR19990071523A (en) | 1995-11-21 | 1999-09-27 | 해리 에이. 루스제 | Inhibition of tumor growth by antisense oligonucleotides against IL-8 and IL-8 receptors |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
EP1007655A1 (en) | 1996-02-15 | 2000-06-14 | National Institutes Of Health | Rnase l activators and antisense oligonucleotides effective to treat rsv infections |
US5877162A (en) | 1996-03-14 | 1999-03-02 | Innovir Laboratories, Inc. | Short external guide sequences |
US5792613A (en) | 1996-06-12 | 1998-08-11 | The Curators Of The University Of Missouri | Method for obtaining RNA aptamers based on shape selection |
US5955590A (en) | 1996-07-15 | 1999-09-21 | Worcester Foundation For Biomedical Research | Conjugates of minor groove DNA binders with antisense oligonucleotides |
US5874566A (en) | 1996-10-25 | 1999-02-23 | Hisamitsu Pharmaceutical Co. Inc. | Il-15 triplex oligonucleotides |
US6051698A (en) | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
US6046004A (en) | 1997-02-27 | 2000-04-04 | Lorne Park Research, Inc. | Solution hybridization of nucleic acids with antisense probes having modified backbones |
US6300483B1 (en) | 1997-06-19 | 2001-10-09 | Ribozyme Pharmaceuticals, Inc. | Compositions inducing cleavage of RNA motifs |
AU7976198A (en) | 1997-06-19 | 1999-01-04 | Ribozyme Pharmaceuticals, Inc. | Hammerhead ribozymes with extended cleavage rule |
JPH1142091A (en) | 1997-07-25 | 1999-02-16 | Toagosei Co Ltd | Anti-sense nucleic acid compound |
US6046319A (en) | 1997-10-22 | 2000-04-04 | University Technologies International, Inc. | Antisense oligodeoxynucleotides regulating expression of TNF-α |
US6007995A (en) | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
US6013522A (en) | 1999-02-23 | 2000-01-11 | Isis Pharmaceuticals Inc. | Antisense inhibition of human Smad1 expression |
US6025198A (en) | 1999-06-25 | 2000-02-15 | Isis Pharmaceuticals Inc. | Antisense modulation of Ship-2 expression |
US6033910A (en) | 1999-07-19 | 2000-03-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of MAP kinase kinase 6 expression |
US20040023870A1 (en) * | 2000-01-21 | 2004-02-05 | Douglas Dedera | Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins |
HU230458B1 (en) | 2000-12-01 | 2016-07-28 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Rna interference mediating small rna molecules |
WO2006052900A2 (en) * | 2004-11-09 | 2006-05-18 | University Of Southern California | Targeted innate immunity |
US20080031887A1 (en) | 2006-06-30 | 2008-02-07 | Joseph Lustgarten | Conjugates for inducing targeted immune responses and methods of making and using same |
KR20110044764A (en) * | 2008-07-28 | 2011-04-29 | 이데라 파마슈티칼즈, 인코포레이티드 | Modulation of toll-like receptor 9 expression by antisense oligonucleotides |
WO2010132622A2 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of California | Anticd20-cpg conjugates and methods of treating b cell malignancies |
-
2017
- 2017-08-02 EP EP17837618.2A patent/EP3496736A4/en not_active Withdrawn
- 2017-08-02 CA CA3032320A patent/CA3032320A1/en not_active Abandoned
- 2017-08-02 AU AU2017306422A patent/AU2017306422A1/en not_active Abandoned
- 2017-08-02 JP JP2019506177A patent/JP2019524787A/en active Pending
- 2017-08-02 WO PCT/US2017/045140 patent/WO2018026943A1/en unknown
- 2017-08-02 CN CN201780059647.3A patent/CN110087665A/en active Pending
- 2017-08-02 US US16/319,935 patent/US11123435B2/en active Active
- 2017-08-02 MX MX2019001364A patent/MX2019001364A/en unknown
- 2017-08-02 KR KR1020197005520A patent/KR20190037273A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130012437A1 (en) * | 2011-07-07 | 2013-01-10 | Tuskegee University | Lytic peptides having anti-proliferative activity against prostate cancer cells |
US20140127241A1 (en) * | 2012-10-30 | 2014-05-08 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
US20150343078A1 (en) * | 2013-01-18 | 2015-12-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | TARGETED SENSITIZATION OF NON-DEL(5q) MALIGNANT CELLS |
WO2016070045A1 (en) * | 2014-10-31 | 2016-05-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tlr9 targeted cytotoxic agents |
WO2016070014A1 (en) * | 2014-10-31 | 2016-05-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tetravalent tlr9 bispecific antibody |
Non-Patent Citations (1)
Title |
---|
See also references of EP3496736A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020102382A1 (en) * | 2018-11-13 | 2020-05-22 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Tlr9-targeted therapeutics |
Also Published As
Publication number | Publication date |
---|---|
US11123435B2 (en) | 2021-09-21 |
CN110087665A (en) | 2019-08-02 |
JP2019524787A (en) | 2019-09-05 |
EP3496736A4 (en) | 2020-05-13 |
EP3496736A1 (en) | 2019-06-19 |
MX2019001364A (en) | 2019-08-01 |
AU2017306422A1 (en) | 2019-01-31 |
KR20190037273A (en) | 2019-04-05 |
US20190192669A1 (en) | 2019-06-27 |
CA3032320A1 (en) | 2018-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meyer et al. | Cell‐specific aptamers as emerging therapeutics | |
Zhou et al. | Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells | |
Zhou et al. | Aptamers: A promising chemical antibody for cancer therapy | |
US8785618B2 (en) | Method of delivering RNA interference and uses thereof | |
Bäumer et al. | Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown | |
EP3105319B1 (en) | Use of mcoln-1 modulators to regulate cell migration | |
US11123435B2 (en) | TLR9 targeted therapeutics | |
US20190167803A1 (en) | Tlr9 targeted cytotoxic agents | |
WO2018192505A1 (en) | Immunomodulatory polynucleotides and uses thereof | |
JP2020537503A (en) | Compositions and Methods for Treating Cancer with Anti-CD19 Immunotherapy | |
JP2017526367A (en) | Methods and compositions for the treatment of cancer | |
JP2023544970A (en) | Compositions and methods for delivery of nucleic acids to cells | |
US20220160762A1 (en) | Engineered immune cells | |
List et al. | TLR9 targeted therapeutics | |
US20220340906A1 (en) | Methods and compositions for the treatment of cancer | |
US20230050022A1 (en) | Compositions and methods related to transferrin receptor-binding aptamers | |
Corogeanu | Targeted delivery of endosomal Toll-like receptor agonists to the tumour microenvironment for the promotion of anti-tumour immunity | |
US20220041682A1 (en) | Tlr9-targeted therapeutics | |
CN118265791A (en) | Spherical nucleic acids for cGAS-STING and STAT3 pathway modulation for immunotherapeutic treatment of cancer | |
KR20240099484A (en) | Therapeutic compounds for erythrocyte-mediated delivery of active pharmaceutical ingredients to target cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17837618 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3032320 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2017306422 Country of ref document: AU Date of ref document: 20170802 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019506177 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20197005520 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017837618 Country of ref document: EP Effective date: 20190304 |